Journal article

HSP90 Inhibition Suppresses Lipopolysaccharide-Induced Lung Inflammation In Vivo

Andrew Lilja, Clare E Weeden, Kate McArthur, Nguyen Thao, Alastair Donald, Zi Xin Wong, Lovisa Dousha, Steve Bozinovski, Ross Vlahos, Christopher J Burns, Marie-Liesse Asselin-Labat, Gary P Anderson



Inflammation is an important component of cancer diathesis and treatment-refractory inflammation is a feature of many chronic degenerative lung diseases. HSP90 is a 90kDa protein which functions as an ATP-dependent molecular chaperone that regulates the signalling conformation and expression of multiple protein client proteins especially oncogenic mediators. HSP90 inhibitors are in clinical development as cancer therapies but the myeleosuppressive and neutropenic effect of first generation geldanamycin-class inhibitors has confounded studies on the effects on HSP90 inhibitors on inflammation. To address this we assessed the ability of Ganetespib, a non-geldanamycin HSP90 blocker, to suppress..

View full abstract


Awarded by Australian National Health and Medical Research Council

Funding Acknowledgements

This work is supported by scholarships, fellowships and grants from the Australian National Health and Medical Research Council (Development Grant 1038895); Victorian State Government Operational Infrastructure Support (OIS) Grant; Australian Cancer Research Foundation; Australian Research Council Queen Elizabeth II Fellowship (MLAL); and, Dyson Bequest funding (Dunn Fellowship to CJB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.